JPH0361428B2 - - Google Patents
Info
- Publication number
- JPH0361428B2 JPH0361428B2 JP59274659A JP27465984A JPH0361428B2 JP H0361428 B2 JPH0361428 B2 JP H0361428B2 JP 59274659 A JP59274659 A JP 59274659A JP 27465984 A JP27465984 A JP 27465984A JP H0361428 B2 JPH0361428 B2 JP H0361428B2
- Authority
- JP
- Japan
- Prior art keywords
- pseudomonas aeruginosa
- human
- type
- antibody
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 61
- 210000004027 cell Anatomy 0.000 claims description 48
- 210000004408 hybridoma Anatomy 0.000 claims description 41
- 239000002158 endotoxin Substances 0.000 claims description 31
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 31
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 20
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 16
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 16
- 208000032536 Pseudomonas Infections Diseases 0.000 claims description 11
- 150000004676 glycans Polymers 0.000 claims description 9
- 150000004804 polysaccharides Polymers 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 description 26
- 208000015181 infectious disease Diseases 0.000 description 16
- 239000000243 solution Substances 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 10
- 230000007910 cell fusion Effects 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000002741 palatine tonsil Anatomy 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 210000005087 mononuclear cell Anatomy 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000003113 dilution method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 2
- 229960005508 8-azaguanine Drugs 0.000 description 2
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- -1 OMP) Polymers 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Description
(ã€) ç£æ¥äžã®å©çšåé
æ¬çºæã¯ãç·è¿èïŒã·ãŠãŒãã¢ãã¹ã»ãšã«ã®ã
ãŒãµãPseudomnas aeruginosaïŒã«å¯Ÿãããã
ã¢ãã¯ããŒãã«æäœãšãã®è£œé æ³ã䞊ã³ã«ããã
æå¹æåãšããç·è¿èææçã®æ²»çå€ã«é¢ããã
ãã®ç®çãšãããšããã¯ãç·è¿èææçã®èšºæå
ã³æ²»ççã«åœ¹ç«ã€ãšããã®ãæç·è¿èããã¢ãã¯
ããŒãã«æäœãæäŸããããšã«ããã (ã) åŸæ¥ã®æè¡ ç·è¿èïŒã·ãŠãŒãã¢ãã¹ã»ãšã«ã®ããŒãµã
Pseudomnas aeruginosaïŒã¯æ¬æ¥ç åæ§ã®äœã
èã§ããããæè¿ã¯ãæçç©è³ªã®æäžã«ããè亀
代æ§å¢æ®ã®çµæãè¬å€èæ§ç·è¿èã«ããææçã
å¢ãããã°ãã°å ç«äžå šããšãããã·ã¹ãã€ãã¯
ãã¢ã€ãããŒã·ã¹ïŒã®ãèæ§ç·ç¶çïŒãç±å·ãã¬
ã³çã®æ£è ã«çºçãé節ãªçç¶ãåããããã«ãª
ã€ãŠããããã®ææçã«ãããŠã¯ãç·è¿èãè¬å€
èæ§ããã€ãŠããããšãå€ããããåæ£è ã®å ç«
åã匱ãŸã€ãŠããçã®ãããæçç©è³ªã«ããæ²»ç
ãå¿ ãããååãªåšåãçºæ®ããªããšããåé¡ã
ãããåŸã€ãŠãæç·è¿èæäœã«ããããããå ç«
æ²»çæ³ãèãããç 究ããã€ã€ããããæªã èšåº
ã«äŸãããã«è³ã€ãŠããªãããŸããç·è¿èææç
ã®æ²»çãé©æ Œã«è¡ãªãããã«ã¯ããã®æ©æ蚺æã
å¿ èŠã§ããããåŸæ¥ã®æè¡æž ãçšããæ¹æ³ã¯æºè¶³
ãã¹ãç¶æ³ã«ãªããšããåé¡ãããããããã®å
é¡ç¹ã解決ããããã«ã¯ãæç·è¿èã¢ãã¯ããŒã
ã«æäœãå¿ èŠã§ããã äžæ¹ãç·è¿èã®è¡šé¢æåãšããŠã¯ããªãå€ç³
ïŒLPSïŒãå€å±€èçœïŒOuter membrane proteinïŒ
OMPïŒããã³æ¯ãã¹ã©ã€ã ç±æ¥ã®å€ç³çãç¥ãã
ãŠããããã®ãã¡LPSã¯ç·è¿èã®è¡æž åã決å®ã
ãïŒâå€ç³åŽéãæããä»ãŸã§ïŒãã16ãŸã§ã®16
çš®é¡ã®è¡æž åïŒHommaã®åé¡ã«ããïŒãç¥ãã
ãŠãããLPSã¯ïŒâå€ç³åŽéã®ä»ã«ã³ã¢ãŒãªãŒãž
ãšã³ããªãããæãããªãããç·è¿èã®å€å±€
ïŒOuter membraneïŒã«ãããããããããïŒâ
ã±ãâïŒâããªãã·ãªã¯ãã³é žãä»ããŠã³ã¢ãŒãª
ãŒãžãšã³ãå€å±€å€ã«äŒžã³ãã³ã¢ãŒãªãŒãžãšã³ãã
âå€ç³åŽéãæŽã«å€åŽã«äŒžå±ããŠãããLPSã«
察ããæäœã¯ããããåç©ã«ãããŠäœãããã
ããææé²åŸ¡çã«åãäºãç¥ãããŠãããæLPS
æäœã¯ãç·è¿èã®LPSãšçµåãããã®æåæäœè€
åäœã«è£äœãçµåããå ç«æº¶èãåãããããã
ãã¯å€åœ¢æ žçœè¡çãªã©ã®é£çŽ°èã«ããåŠçããã
çäœãç·è¿èææçããå ããäºãã§ãããšèšã
ããŠãããç·è¿èã®ææãæç«ããŠããæ£è ã§
ã¯ãç·è¿èæåãå€ããæLPSæäœãäžè¶³ã«ãªã
ãã¡ã§ããããããé²ãæ²»çããããã«ãåŸæ¥ã
ãããã®è¡æ¶²ãã調補ããIgG補å€ã䜿ãããŠã
ããããã®è£œå€ã«å«ãŸããŠããç·è¿èã®æäœäŸ¡ã¯
極ããŠå°ãªããæææ²»çäžååã§ã¯ãªãã€ãã ãšããã§ã现èèåã®æè¡ãçšããŠãç¹ç°çãª
æäœãç£çããããããŠã¯æ»æ» ããéåœã«ãããª
ã³ãçåã¯ïŒ¢çŽ°èïŒæäœç£ç现èïŒãšãå¹é€åšã®
äžã§æ°žä¹ ã«å¢æ®ãã€ã¥ããããšããŒã现èïŒéªšé«
è «çŽ°èïŒãèåãããããšã«ãããç¹ç°æäœãæ°ž
ç¶çã«ç£çåæ³ãããã€ããªããŒãïŒèå现èïŒ
æ ªãæš¹ç«ãããæ¹æ³ã¯å ¬ç¥ã§ããããããæ¹æ³ã«
ãã€ãŠäœæããããã€ããªããŒããç£çããã¢ã
ã¯ããŒãã«æäœã¯ãé«ã粟床ãšä¿¡é ŒåºŠããã€çŽç²
ãªååŠè©Šè¬ãšããŠãæ€æ»è©Šè¬ãæšèè©Šè¬ãã¢ãã€
ããã€ãŒã¯ãããã°ã©ãã€ãŒãªã©ã«å¿çšãã§ãã
ä»ãåçš®çŸç ã®æ²»çè¬ãäºé²è¬ãšããŠã®å¿çšãæ
åŸ ã§ãããã®ã§ããã ã¢ãã¯ããŒãã«ãªæç·è¿èæäœãåŸãããšãã
å Žåã«ã¯ãæç·è¿èæäœç£ç现èãšããšããŒã现
èãšãèåãããã¯ããŒãã³ã°ã«ãã€ãŠæç·è¿è
æäœç£çæ§ã®ãã€ããªããŒããåŸãã°ããããšã¯
äžè¬è«ãšããŠã¯ç¥ãããŠããããããŠãå ·äœçã«
ã¯ãäŸãã°ãç¹éæ59â29622å·å ¬å ±ã«ã¯ãç·è¿
èã®LPSã§å ç«ãããBALBïŒïŒ£ããŠã¹ã®èŸè现
èïŒæäœç£ç现èïŒãšãããŠã¹ã®ããšããŒã现è
ïŒP3â 63âAg ïŒâU1æ ªïŒãšãèåãããã€
ããªããŒããåŸããããã¯ããŒãã³ã°ããããšã«
ãã€ãŠãã¢ãã¯ããŒãã«ãªæç·è¿èããŠã¹æäœã
ç£çããããŠã¹âããŠã¹ãã€ããªããŒããåŸãã
ãšããããŠåŸãããããŠã¹ã¢ãã¯ããŒãã«æäœ
ã¯ãç·è¿èææã«é²åŸ¡å¹æã瀺ããããšãé瀺ã
ããŠããã (ã) çºæã解決ããããšããåé¡ç¹ 以äžã®ããšããæç·è¿èæäœã«é¢ããŠã¯ãå ·äœ
çãªæåäŸã¯æç·è¿èããŠã¹ã¢ãã¯ããŒãã«æäœ
ã ãã§ãããããããããã®ç æ°ã®èšºæãæ²»çã®
ããã«ã¯ãåçš®ã¿ã³ãã¯ã§ããæç·è¿èããæäœ
ã®æ¹ãæçšã§ãã€å®å šã§ããããã®ããã«ã¯ãã
ãã®æäœç£ç现èãçšããŠããŠã¹âãããã€ããª
ããŒããããâãããã€ããªããŒããæš¹ç«ããå¿
èŠããããããããªãããåç©ã®å Žåãšç°ãªãã
ããã®å Žåã«ã¯ãããããããããå€éã®ç·è¿è
ããã®è¡šé¢æåã§å ç«ããæå¹ã«åºæ¿ãããæäœ
ç£ç现èãæ¡åããŠçŽ°èèåã«çšãããšãã€ãæ¹
æ³ããšãããã«ã¯ãããªãã®ã§ãé©åãªæäœç£ç
现èã®æ¡åã»èª¿æŽãå°é£ã§ãããšãã€ãåé¡çã
ãããæªã æ確ãªæåäŸã®å ±åããªãã (ã) åé¡ç¹ã解決ããããã®æ段ïŒãã®äžïŒ æ¬çºæè ãã¯ãæç·è¿èããæäœãåŸããã
ã«ãããŠã¹âãããã€ããªããŒãã«é¢ãéæç 究
ãè¡ãªã€ãçµæã现èèåæ³ãšåœ¢è³ªè»¢ææ³ã«ãã€
ãŠãç¹å®ã®æç·è¿èæäœãåŸãããšãã§ããã å³ã¡ãæ¬çºæã¯ãç·è¿èã®è¡æž åãïŒåãïŒ
åãïŒåãïŒååã³10åã®ããããã§ããç·è¿è
ã®ãªãå€ç³ã®ïŒ¯âå€ç³åŽéãèªèããæ§è³ªãæã
ãããã®æç·è¿èæäœç£ç现èãšããŠã¹ã®ããšã
ãŒã现èãšã®ããŠã¹âãããã€ããªããŒãç±æ¥ã®
æç·è¿èããã¢ãã¯ããŒãã«IgGæäœã§ããã ãããã¢ãã¯ããŒãã«æäœãããã®æç·è¿èæ
äœç£ç现èãšããŠã¹ã®ããšããŒã现èãšã®ããŠã¹
âãããã€ããªããŒããäœæãã該ãã€ããªããŒ
ãåã³ïŒåã¯ããã«ç±æ¥ãã现èæ ªãå¹é€ããå¹
é€ç©ããç·è¿èã®ãªãå€ç³ã«çµåããæ§è³ªãæã
ãããã¢ãã¯ããŒãã«æäœãæ¡åããæ¹æ³ã«ãã€
ãŠåŸãããã æ¬çºæã«ãããŠããã®æäœç£ç现èãšã¯ããã
ã®ãªã³ãçïŒåã¯ïŒ¢çŽ°èïŒã§ãã€ãŠãæäœãåæ³
ããŠããåã¯åæ³ããèœåãæã€ã现èãããã
ããã¯èŸèããªã³ãç¯ãæ«æ¢¢è¡ã骚é«ãææ¡ãã¢
ããã€ãçã®çŽ°èã®äžã«å«ãŸããŠãããæ¬çºæã®
ç®çã®ããã«ã¯ããããªããœãŒã¹ã®ãªã³ãçã§ã
çšããããšãã§ãããã奜ãŸããã®ã¯ææ¡è ºåã¯
èŸèããæ¡åããããã®ã§ããã ããŠã¹ã®ããšããŒã现èãšããŠã¯ãïŒâã¢ã¶ã°
ã¢ãã³èæ§æ ªãçšããã®ãæå©ã§ãããå ¬ç¥ã®ã
ã®ãšããŠã¯ãBALBïŒïŒ£ããŠã¹ã®P3âX63â
Ag8ãP3âX63âAg8âU1ãP3âNS1ïŒïŒâ
Ag4âïŒãP3âX63âAg8âïŒïŒïŒïŒïŒãSP2ïŒ
âAg14ãFOãMPC11â45.6TG1.7ãªã©ãã
ãã æ¬çºæã«ãããŠã¯ããŸããæåã§ããç¹å®ã®
LPSãæããç·è¿èãéžã¶ã次ã«ããã®ãªã³ãç
ãææ¡è ºããªã³ãç¯ãèŸèåã³æ«æ¢¢è¡çã®çµç¹ã
ãã¢ããã¯ãªã¢ãŒã»ã«ïŒåæ žçŽ°èïŒãšããŠèª¿æŽã
ãããã®ã¢ããã¯ãªã¢ãŒã»ã«ãïŒæ¥ãïŒæ¥ãããŒ
ã¯ãŠã€ãŒããã€ããžãšã³çã®ãã€ããžãšã³ã®æ·»å
ãããã¯ç¡æ·»å ã®æ¡ä»¶äžã§ãïŒïŒ CO2ã€ã³ããŠã
ãŒã¿ãŒã§å¹é€ãããã®å¹é€äžæž 液äžã®æäœããå
èšç·è¿èãåºå®ãããã¬ãŒãã§é µçŽ æäœæ³ã«ãã
枬å®ããæãŸããã¢ãã¯ãªã¢ãŒã»ã«ãå«ãçµç¹ã
éžã¶ã次ãã§ããã®çµç¹ã®ãªã³ãçãšããšããŒã
现èãèåããããã€ããªããŒãã®ç°è³ªéèœã圢
æãããã现èèåã¯å ¬ç¥ã®æ¹æ³ã§è¡ãªãããšã
ã§ãããäŸãã°ãæäœç£ç现èãšããšããŒã现è
èã10ïŒïŒãïŒïŒ10ã奜ãŸããã¯ïŒïŒïŒãïŒïŒïŒ
ã®æ¯çã§æ··åããé©åœãªçŽ°èèåçšæº¶æ¶²ãäŸãã°
çŽ35ïŒ ããªãšãã¬ã³ã°ãªã³ãŒã«ïŒååé1000ã
6000çšåºŠïŒããã³çŽ7.5ïŒ ãžã¡ãã«ã¹ã«ããã·ã
ãå«ãRPMI1640ãå ããŠã宀枩ã37âã§ïŒãæ°
åéæ¹æãããã®åŸ10ïŒ FCSå RPMI1640ã§åŸã
ã«åžéããæŽæµã®åŸHATïŒããããµã³ãã³âã¢
ãããããªã³âãããžã³ïŒéžæå¹é€æ¶²ã«ãŠçŽ°èæ¿
床ãïŒãïŒÃ105åïŒmlãšãªãããã«èª¿æŽããã
ããã0.2mlãã€ãäŸãã°96ç©Žãã¬ãŒãã«å泚ãã
ïŒïŒ CO2ãå«ã空æ°äžã§35ã38âã§ïŒãïŒæéå¹
é€ãããHATå¹é€æ¶²äžã§ã¯ãã€ããªããŒãã®ã¿
ãååšããïŒâã¢ã¶ã°ã¢ãã³èæ§ã®ããšããŒã现
èåã³ããšããŒãå士ã®èå现èã¯çåãåŸãªã
ïŒæªèåã®æäœç£ç现èã¯æ°æ¥ã§æ»æ» ãããïŒæ¬¡
ã«ããã®ãã€ããªããŒãéèœãããç·è¿èLPSã«
察ãç¹ç°çãªããã¢ãã¯ããŒãã«æäœãåæ³ãã
ãã®ã ãéžå¥ããããã®éžå¥å·¥çšã¹ã¯ãªãŒãã³ã°
ã¯ãç°ãªããã€ããªããŒãããç£çãããããã¢
ãã¯ããŒãã«æäœããç®çãšããè¡æž åãæãã
ç·è¿èåã¯ç·è¿èLPSãåºå®ãããã¬ãŒããçšã
ãŠãé µçŽ æäœæ³ãçšããŠè¡ãªãäºãã§ãããå šãŠ
ã®ç·è¿èã®è¡æž åã«åå¿ããããã¢ãã¯ããŒãã«
æäœãåŸãçºã«ã¯ã16çš®é¡ã®ç°ãè¡æž åã®ç·è¿è
ã䜿çšããªããŠã¯ãªããªãããããã®ç·è¿èã¯ã
ã¢ã¡ãªã«ã³ã»ã¿ã€ãã«ã«ãã€ãŒã³ã¬ã¯ã·ãšã³
ïŒATCCïŒããå ¥æã§ããã ç®çãšããç·è¿èã«å¯Ÿããã¢ãã¯ããŒãã«æäœ
ãåæ³ãããã€ããªããŒãã¯ã次ã«ã¯ããŒãã³ã°
ã«ããã¯ããŒã³å现èã«ããªããŠã¯ãªããªããã
ã®å·¥çšã¯ãå ·äœçã«ã¯è»å¯å€©æ³ãçšãè¡ãäºãã§
ãããçŽïŒãïŒé±éåŸãè»å¯å€©äžã§çè²ããã³ã
ããŒãæŸããåã³é µçŽ æäœæ³ã§ç·è¿èã«å¯Ÿããæ
äœæŽ»æ§ã調ã¹éžå¥ãããéžå¥ãããã€ããªããŒã
ãå¹é€ããŠãææã®LPSç¹ç°çããã¢ãã¯ããŒã
ã«æäœãçæãããã ã¢ãã¯ããŒãã«æäœãåŸãããã®ããäžã€ã®æ¹
æ³ã¯ãããã®æç·è¿èæäœç£ç现èããšãã¹ã¿ã€
ã³ã»ããŒã»ãŠã€ã«ã¹ïŒEpsteinâBarr Virusã以
äžïŒ¥âãŠã€ã«ã¹ãšç¥ç§°ããïŒãææãããŠåœ¢è³ª
転æ现èãäœæãã該圢質転æ现èåã³ïŒåã¯ã
ãã«ç±æ¥ãã现èæ ªãå¹é€ããå¹é€ç©ããç·è¿è
ã®ãªãå€ç³ã«çµåããæ§è³ªãæããããã¢ãã¯ã
ãŒãã«æäœãæ¡åããæ¹æ³ã§ããã âãŠã€ã«ã¹ã¯ãããŒããããªã³ãè «ã錻åœ
é ã¬ã³ã®åå ãŠã€ã«ã¹ãšãããŠããããã«ãã¹ãŠ
ã€ã«ã¹çŸ€ã«å±ãããŠã€ã«ã¹ã§ãããåèšãšåæ§ãª
ããã®ãªã³ãçã®ã¢ããã¯ãªã¢ãŒã»ã«ãâãŠ
ã€ã«ã¹ã«ææãããçŽïŒãïŒé±éãïŒïŒ CO2ã€ã³
ããŠããŒã¿ã§å¹é€ããå€ãã®ç°è³ªéèœããæã圢
質転æ现èïŒãã©ã³ã¹ããªãŒã ãã»ã«ïŒã圢æã
ããã次ã«ããã®åœ¢è³ªè»¢æ现èãããç·è¿èLPS
ã«å¯Ÿãç¹ç°çãªããã¢ãã¯ããŒãã«æäœãåæ³ã
ããã®ã ãããåèšãšåæ§ãªæ¹æ³ã§éžå¥ãããã
ããŠãåèšãšåæ§ã«ããŠãã¯ããŒã³åããã圢質
転æ现èãåŸãããšãã§ããã 次ã«ãæ¬çºæã«ãããŠã¯ãéžæãããã€ããªã
ãŒãåã¯åœ¢è³ªè»¢æ现èãå¹é€ããŠãææã®ç¹ç°ç
ããã¢ãã¯ããŒãã«æäœãçæãããã ã¯ããŒãã³ã°ã«ãã€ãŠéžæããããæç·è¿èã
ãæäœãç£çããããŠã¹âãããã€ããªããŒãå
ã¯ãã圢質転æ现èã¯åçµããŠä¿åããããšãã§
ãããŸãããããé©åœãªæ¹æ³ã§å€§éã«å¹é€ããã
ãšãã§ããããããŠãå¹é€äžæž ããç·è¿èLPSã«
ç¹ç°çã«çµåããã¢ãã¯ããŒãã«ãªæç·è¿èãã
æäœãåŸãããšãã§ããããŸããããã现èãå
ç©ã«ç§»æ€ããŠè «çåãããã®è ¹æ°Žãè¡æž ããæç·
è¿èããæäœãåŸãããšãã§ãããæç·è¿èãã
æäœã®ç²Ÿè£œã¯ãã¢ãã¯ããŒãã«æäœãçšããã¢ã
ã€ããã€ã¯ãããã°ã©ãã€ãŒçã®æ¹æ³ã«ãã€ãŠè¡
ãªãããã (ã) äœçš æç·è¿èLPSããã¢ãã¯ããŒãã«æäœã¯ãç·è¿
èLPSã«ç¹ç°çã«çµåããŠè£äœã«ããç·è¿èãå
ç«æº¶èãããããŸããç·è¿èææããŠã¹ã¢ãã«å®
éšã®ç³»ã§ããŠã¹ãææããé²åŸ¡ããããšãã§ã
ãã æ¬çºæã®ããã¢ãã¯ããŒãã«æäœã¯ãäºãã«æ··
åãããç·è¿èã®å šãŠã®16çš®ã®è¡æž åã«çµåãã
ãäºãã§ãããæç·è¿èLPSããã¢ãã¯ããŒãã«
æäœã¯ãè¡æž åç¹ç°çã«çµåããææã¢ãã«å®éš
ç³»ã§ææé²åŸ¡èœãçºæ®ãããããªãã¡ãããè¡æž
åã«ç¹ç°çãªããã¢ãã¯ããŒãã«æäœã¯ãåãè¡
æž åã®ç·è¿èã«ã¯ã100ïŒ çµåãåŸãããç°ãè¡
æž åã®ç·è¿èã«ã¯å šãçµåã§ããªããåŸã€ãŠãå
ããã¢ãã¯ããŒãã«æäœãæ··ãåããäºã«ããã
çŸåšããã€ãŠããå šãŠã®è¡æž åã®ç·è¿èã«çµåã
ãããäºãã§ããã (ã) åé¡ç¹ã解決ããããã®æ段ïŒãã®äºïŒ æ¬çºæã®ç·è¿èã®ãªãå€ç³ãèªèããæ§è³ªãæ
ããæç·è¿èããã¢ãã¯ããŒãã«æäœã¯ãä»ã®é
åžžã®å»è¬å©å€ãšå ±ã«å»è¬è£œå€ãšããããšãã§ãã
ããã¯ããåã³åç©ã®ç·è¿èææçã®æ²»çå€ãšã
ãŠçšãããããããã補å€ã«ãããŠã¯ãå šãŠã®è¡
æž åã«å¯Ÿå¿ããã¢ãã¯ããŒãã«æäœãæ··åããã
ãšã¯å¿ ãããå¿ èŠã§ã¯ãªããå°ãªããšãè¡æž åã
ïŒåãïŒåãïŒåãïŒååã³10åã®ç·è¿èã«å¯Ÿã
ãæç·è¿èããã¢ãã¯ããŒãã«æäœãå«ã補å€ãš
ããã°ãç·è¿èææçã®70ïŒ ä»¥äžãæ²»çããããš
ãã§ããã æ¬çºæã®ããã¢ãã¯ããŒãã«æäœã®æäžæ¹æ³ã¯
åã ã®ç¶æ³ããšãã°åŠçœ®ãã¹ãç·è¿èææçã®ç¶
æ³ã«ããå€åããåæ§ã«æäžéåã³æäžã®é »åºŠã«
å¿ããŠå€åãããäžè¬ã«ãæäœã¯æäžåã«éæ¯æ§
ã®å»è¬äžèš±å®¹ãåŸããã€ãªã¢ç©è³ªãäŸãã°ãéåžž
ã®é£å¡©æ°Žãšæ··åãããä»»æã®å»çäžé©åœãªæ¹æ³ã
äŸãã°ãéèæäžã«ãã€ãŠæäžããããäžè¬ã«ã
æäœã¯ãã€ãªã¢äžã«çŽ0.5ÎŒïœæäœïŒmlã500ÎŒïœæ
äœïŒmlã®æ¿åºŠã§ååšããããïŒåã®æäžããæäœ
ã®éã¯ãäžè¬ã«äœéïŒKgå€ã10ÎŒïœã10mgã®æäœ
ã®ç¯å²ã§ãããæãå Žåã«ã¯ãïŒå以äžã®äžé£ã®
æäžãå¿ èŠãšãããã (ã) å®æœäŸ 以äžãå®æœäŸã«ããæ¬çºæã詳述ããã å®æœäŸ ïŒ (1) æç·è¿èæäœç£ç现èã®éžå¥ ïŒäººã®ææ¡çæ£è ããïŒãããã®ææ¡è ºã
åŸããããããã¢ã€ã³ãŒã«ããã¯ãçšãã¢ãã
ã¯ãªã¢ãŒã»ã«ã調補ããã现èæ¿åºŠãïŒÃ
106ïŒmlã«ãªãæ§ã«ãã¢ããã¯ãªã¢ãŒã»ã«ãå¹
é€æ¶²ïŒ¡ïŒRPMI1640ïŒ10ïŒ èå çè¡æž ïŒ2mMã°
ã«ã¿ãã³ïŒ1mMãã«ãã³é žïŒ0.02mgïŒmlã»ãª
ã³ïŒ80ÎŒïœïŒmlã²ã³ã¿ãã€ã·ã³ïŒã«æµ®éããã
ããã«ãããŒã¯ãŠã€ãŒããã€ããžãšã³
ïŒPWMïŒã20ÎŒïœïŒmlã«ãªãæ§ã«å ããããã®
è©Šæã200ÎŒã¥ã€å¹é€ãã¬ãŒãã«å ¥ããCO2ã€
ã³ããŠããŒã¿ïŒïŒïŒ CO2ïŒã§ïŒãïŒæ¥å¹é€ã
ãããã®åŸãããããã®å¹é€äžæž 液100ÎŒã
ç·è¿èãã³ãŒããããã¬ãŒãã«ç§»ããé µçŽ æäœ
æ³ã§æž¬å®ãè¡ã€ããšãããïŒãããã ã匷ãæ
ç·è¿èæäœãç£çããŠããããã®ãããã®ã¢ã
ãã¯ãªã¢ãŒã»ã«ããããŠã¹ããšããŒã现èP3
â 63âAg8âUIïŒä»¥äžP3UIãšç¥èšããïŒãš
ã®çŽ°èèåã«çšããã (2) 现èèå åãã€ãŠP3UIãå¹é€æ¶²ïŒ¡äžã§å¹é€ããŠãã
ãã䜿çšæã®çŽ°èæ¿åºŠã¯ïŒÃ105åïŒmlã§ãã€
ããäžèšã®æç·è¿èæäœç£çãããããŠããæ
æ¡è ºãããã®ãªã³ãçãšP3UIãããããã
å¥ã ã«ç¡è¡æž RPMI1640ã§ïŒåæŽæµãããã
ãŠããªã³ãçãšïŒÃ106åã®P3UIãšãè©Šéšç®¡ã®
äžã§äžç·ã«ãã次ãã§1500rpmã§ïŒåéé å¿
ããäžæž ãæšãŠãã现èãã¬ããããè©Šéšç®¡ã«
ãããããšã«ãã€ãŠãããåæ£ããããããã«
0.5mlã®ããªãšãã¬ã³ã°ãªã³ãŒã«æ¶²
ïŒRPMI1640 75mlÃããªãšãã¬ã³ã°ãªã³ãŒã«
1500 3.5mlïŒãžã¡ãã«ã¹ã«ãããµã€ã0.75mlïŒ
ïŒPEG液ãšç¥èšããïŒãå ããŠã现èãããã
ãã«æµ®éããããïŒååŸã«0.5mlã®RPMI1640
ãå ããããã«ïŒååŸã«ïŒmlRPMIãããã«ïŒ
ååŸã«ïŒmlã®HATå¹é€æ¶²ïŒRPMI1640ïŒ20ïŒ
èå çè¡æž ïŒ80ÎŒïœïŒmlã²ã³ã¿ãã€ã³ã·ã³ïŒ
95ÎŒMããããµã³ãã³ïŒ0.4ÎŒMã¢ãããããªã³
ïŒ1.6ÎŒMãããžã³ïŒãããã«ïŒååŸã«ã¯ïŒmlã®
HATå¹é€æ¶²ãå ãããæåŸã«ãHATå¹é€æ¶²
ã§25ml现èæµ®é液ãšããããããå¹é€ãã¬ãŒã
ïŒ96ç©ŽïŒïŒæã«èããŠã37âãïŒïŒ CO2å«æ空
æ°äžã§å¹é€ãããäžé±éæ¯ã«åéã®å¹é€æ¶²ãæ°
ããHTå¹é€æ¶²ïŒHATãããé€å»ãããã®ïŒ
ã§äº€æããŠãããã€ããªããŒããåŸãã (3) ã¯ããŒãã³ã°åã³å¹é€ åŸããããã€ããªããŒãã®äžæž ããã«ããªã³
æ»æ» ç·è¿èãã³ãŒãã€ã³ã°ãããã¬ãŒããçšã
ãŠELISAæ³ã§æž¬å®ãè¡ã€ãçµæãç·è¿èè¡æž
åHommaã®type5ã«çµåããããã¢ãã¯ããŒ
ãã«æäœP3ãåŸããããã§ãP3ãç£çããã
ã€ããªããŒãããïŒåéçåžéæ³ã«ããã¯ããŒ
ãã³ã°ãè¡ãïŒ96ç©Žãã¬ãŒãïŒæïŒæçµçã«
P3D9ãšããããã¢ãã¯ããŒãã«æäœïŒIgGã
λïŒãç£çããããŠã¹âãããã€ããªããŒãã
åŸãã æ¬ãã€ããªããŒãããç¡è¡æž å¹å°RDFïŒ
TESå¹å°ïŒProc.Natl.Acad.Sci.USA vol.79ã
1158â1162åç §ïŒïŒã§å¹é€ãè¡ããP3D9ã
å«ãå¹é€æ¶²ãéå€æ¿ŸéèPM30ïŒã¢ãã³ã³ç€Ÿè£œïŒ
ãçšããŠæ¿çž®ãè¡ãã30mlãšããããããŠ
DEAEâSephacelã§ã«ã©ã ã¯ããããè¡ãã
P3D9ã粟補ã12mgãåŸãã (4) ã¢ãã¯ããŒãã«æäœã®ææé²åŸ¡å¹æ P3D9ã®ææé²åŸ¡å¹æã調ã¹ããããç·è¿è
èšåºåé¢æ ªïŒ®âïŒåã³97ãéžã°ãããâïŒã®
è¡æž åã¯ãHomma type5ã§ã97ã®ããã¯
Homma type7ã§ãã€ãã ïŒé±ä»€ã®ICRããŠã¹ïŒéãäœé16ã20ïœïŒã«
ïŒåã¯4LD50ã®ïŒ®âïŒæ ªåã¯97æ ªãè ¹è ã«æäž
ãããïŒäžçŸ€10å¹ïŒãããŠãïŒæéåŸã«ã10ÎŒ
ïœåã¯1ÎŒïœã®P3D9ãè ¹è å ã«æäžãããããž
ãã€ãã³ã³ãããŒã«ãšããŠãããè¡æž ãã粟補
ããIgGãè ¹è å ã«æäžããããã¬ãã€ãã³ã³
ãããŒã«ãšããŠãççé£å¡©æ°Žãåéæäžããã
ïŒæ¥é芳å¯åŸã®çµæã第ïŒè¡šã«ç€ºããã
ãŒãµãPseudomnas aeruginosaïŒã«å¯Ÿãããã
ã¢ãã¯ããŒãã«æäœãšãã®è£œé æ³ã䞊ã³ã«ããã
æå¹æåãšããç·è¿èææçã®æ²»çå€ã«é¢ããã
ãã®ç®çãšãããšããã¯ãç·è¿èææçã®èšºæå
ã³æ²»ççã«åœ¹ç«ã€ãšããã®ãæç·è¿èããã¢ãã¯
ããŒãã«æäœãæäŸããããšã«ããã (ã) åŸæ¥ã®æè¡ ç·è¿èïŒã·ãŠãŒãã¢ãã¹ã»ãšã«ã®ããŒãµã
Pseudomnas aeruginosaïŒã¯æ¬æ¥ç åæ§ã®äœã
èã§ããããæè¿ã¯ãæçç©è³ªã®æäžã«ããè亀
代æ§å¢æ®ã®çµæãè¬å€èæ§ç·è¿èã«ããææçã
å¢ãããã°ãã°å ç«äžå šããšãããã·ã¹ãã€ãã¯
ãã¢ã€ãããŒã·ã¹ïŒã®ãèæ§ç·ç¶çïŒãç±å·ãã¬
ã³çã®æ£è ã«çºçãé節ãªçç¶ãåããããã«ãª
ã€ãŠããããã®ææçã«ãããŠã¯ãç·è¿èãè¬å€
èæ§ããã€ãŠããããšãå€ããããåæ£è ã®å ç«
åã匱ãŸã€ãŠããçã®ãããæçç©è³ªã«ããæ²»ç
ãå¿ ãããååãªåšåãçºæ®ããªããšããåé¡ã
ãããåŸã€ãŠãæç·è¿èæäœã«ããããããå ç«
æ²»çæ³ãèãããç 究ããã€ã€ããããæªã èšåº
ã«äŸãããã«è³ã€ãŠããªãããŸããç·è¿èææç
ã®æ²»çãé©æ Œã«è¡ãªãããã«ã¯ããã®æ©æ蚺æã
å¿ èŠã§ããããåŸæ¥ã®æè¡æž ãçšããæ¹æ³ã¯æºè¶³
ãã¹ãç¶æ³ã«ãªããšããåé¡ãããããããã®å
é¡ç¹ã解決ããããã«ã¯ãæç·è¿èã¢ãã¯ããŒã
ã«æäœãå¿ èŠã§ããã äžæ¹ãç·è¿èã®è¡šé¢æåãšããŠã¯ããªãå€ç³
ïŒLPSïŒãå€å±€èçœïŒOuter membrane proteinïŒ
OMPïŒããã³æ¯ãã¹ã©ã€ã ç±æ¥ã®å€ç³çãç¥ãã
ãŠããããã®ãã¡LPSã¯ç·è¿èã®è¡æž åã決å®ã
ãïŒâå€ç³åŽéãæããä»ãŸã§ïŒãã16ãŸã§ã®16
çš®é¡ã®è¡æž åïŒHommaã®åé¡ã«ããïŒãç¥ãã
ãŠãããLPSã¯ïŒâå€ç³åŽéã®ä»ã«ã³ã¢ãŒãªãŒãž
ãšã³ããªãããæãããªãããç·è¿èã®å€å±€
ïŒOuter membraneïŒã«ãããããããããïŒâ
ã±ãâïŒâããªãã·ãªã¯ãã³é žãä»ããŠã³ã¢ãŒãª
ãŒãžãšã³ãå€å±€å€ã«äŒžã³ãã³ã¢ãŒãªãŒãžãšã³ãã
âå€ç³åŽéãæŽã«å€åŽã«äŒžå±ããŠãããLPSã«
察ããæäœã¯ããããåç©ã«ãããŠäœãããã
ããææé²åŸ¡çã«åãäºãç¥ãããŠãããæLPS
æäœã¯ãç·è¿èã®LPSãšçµåãããã®æåæäœè€
åäœã«è£äœãçµåããå ç«æº¶èãåãããããã
ãã¯å€åœ¢æ žçœè¡çãªã©ã®é£çŽ°èã«ããåŠçããã
çäœãç·è¿èææçããå ããäºãã§ãããšèšã
ããŠãããç·è¿èã®ææãæç«ããŠããæ£è ã§
ã¯ãç·è¿èæåãå€ããæLPSæäœãäžè¶³ã«ãªã
ãã¡ã§ããããããé²ãæ²»çããããã«ãåŸæ¥ã
ãããã®è¡æ¶²ãã調補ããIgG補å€ã䜿ãããŠã
ããããã®è£œå€ã«å«ãŸããŠããç·è¿èã®æäœäŸ¡ã¯
極ããŠå°ãªããæææ²»çäžååã§ã¯ãªãã€ãã ãšããã§ã现èèåã®æè¡ãçšããŠãç¹ç°çãª
æäœãç£çããããããŠã¯æ»æ» ããéåœã«ãããª
ã³ãçåã¯ïŒ¢çŽ°èïŒæäœç£ç现èïŒãšãå¹é€åšã®
äžã§æ°žä¹ ã«å¢æ®ãã€ã¥ããããšããŒã现èïŒéªšé«
è «çŽ°èïŒãèåãããããšã«ãããç¹ç°æäœãæ°ž
ç¶çã«ç£çåæ³ãããã€ããªããŒãïŒèå现èïŒ
æ ªãæš¹ç«ãããæ¹æ³ã¯å ¬ç¥ã§ããããããæ¹æ³ã«
ãã€ãŠäœæããããã€ããªããŒããç£çããã¢ã
ã¯ããŒãã«æäœã¯ãé«ã粟床ãšä¿¡é ŒåºŠããã€çŽç²
ãªååŠè©Šè¬ãšããŠãæ€æ»è©Šè¬ãæšèè©Šè¬ãã¢ãã€
ããã€ãŒã¯ãããã°ã©ãã€ãŒãªã©ã«å¿çšãã§ãã
ä»ãåçš®çŸç ã®æ²»çè¬ãäºé²è¬ãšããŠã®å¿çšãæ
åŸ ã§ãããã®ã§ããã ã¢ãã¯ããŒãã«ãªæç·è¿èæäœãåŸãããšãã
å Žåã«ã¯ãæç·è¿èæäœç£ç现èãšããšããŒã现
èãšãèåãããã¯ããŒãã³ã°ã«ãã€ãŠæç·è¿è
æäœç£çæ§ã®ãã€ããªããŒããåŸãã°ããããšã¯
äžè¬è«ãšããŠã¯ç¥ãããŠããããããŠãå ·äœçã«
ã¯ãäŸãã°ãç¹éæ59â29622å·å ¬å ±ã«ã¯ãç·è¿
èã®LPSã§å ç«ãããBALBïŒïŒ£ããŠã¹ã®èŸè现
èïŒæäœç£ç现èïŒãšãããŠã¹ã®ããšããŒã现è
ïŒP3â 63âAg ïŒâU1æ ªïŒãšãèåãããã€
ããªããŒããåŸããããã¯ããŒãã³ã°ããããšã«
ãã€ãŠãã¢ãã¯ããŒãã«ãªæç·è¿èããŠã¹æäœã
ç£çããããŠã¹âããŠã¹ãã€ããªããŒããåŸãã
ãšããããŠåŸãããããŠã¹ã¢ãã¯ããŒãã«æäœ
ã¯ãç·è¿èææã«é²åŸ¡å¹æã瀺ããããšãé瀺ã
ããŠããã (ã) çºæã解決ããããšããåé¡ç¹ 以äžã®ããšããæç·è¿èæäœã«é¢ããŠã¯ãå ·äœ
çãªæåäŸã¯æç·è¿èããŠã¹ã¢ãã¯ããŒãã«æäœ
ã ãã§ãããããããããã®ç æ°ã®èšºæãæ²»çã®
ããã«ã¯ãåçš®ã¿ã³ãã¯ã§ããæç·è¿èããæäœ
ã®æ¹ãæçšã§ãã€å®å šã§ããããã®ããã«ã¯ãã
ãã®æäœç£ç现èãçšããŠããŠã¹âãããã€ããª
ããŒããããâãããã€ããªããŒããæš¹ç«ããå¿
èŠããããããããªãããåç©ã®å Žåãšç°ãªãã
ããã®å Žåã«ã¯ãããããããããå€éã®ç·è¿è
ããã®è¡šé¢æåã§å ç«ããæå¹ã«åºæ¿ãããæäœ
ç£ç现èãæ¡åããŠçŽ°èèåã«çšãããšãã€ãæ¹
æ³ããšãããã«ã¯ãããªãã®ã§ãé©åãªæäœç£ç
现èã®æ¡åã»èª¿æŽãå°é£ã§ãããšãã€ãåé¡çã
ãããæªã æ確ãªæåäŸã®å ±åããªãã (ã) åé¡ç¹ã解決ããããã®æ段ïŒãã®äžïŒ æ¬çºæè ãã¯ãæç·è¿èããæäœãåŸããã
ã«ãããŠã¹âãããã€ããªããŒãã«é¢ãéæç 究
ãè¡ãªã€ãçµæã现èèåæ³ãšåœ¢è³ªè»¢ææ³ã«ãã€
ãŠãç¹å®ã®æç·è¿èæäœãåŸãããšãã§ããã å³ã¡ãæ¬çºæã¯ãç·è¿èã®è¡æž åãïŒåãïŒ
åãïŒåãïŒååã³10åã®ããããã§ããç·è¿è
ã®ãªãå€ç³ã®ïŒ¯âå€ç³åŽéãèªèããæ§è³ªãæã
ãããã®æç·è¿èæäœç£ç现èãšããŠã¹ã®ããšã
ãŒã现èãšã®ããŠã¹âãããã€ããªããŒãç±æ¥ã®
æç·è¿èããã¢ãã¯ããŒãã«IgGæäœã§ããã ãããã¢ãã¯ããŒãã«æäœãããã®æç·è¿èæ
äœç£ç现èãšããŠã¹ã®ããšããŒã现èãšã®ããŠã¹
âãããã€ããªããŒããäœæãã該ãã€ããªããŒ
ãåã³ïŒåã¯ããã«ç±æ¥ãã现èæ ªãå¹é€ããå¹
é€ç©ããç·è¿èã®ãªãå€ç³ã«çµåããæ§è³ªãæã
ãããã¢ãã¯ããŒãã«æäœãæ¡åããæ¹æ³ã«ãã€
ãŠåŸãããã æ¬çºæã«ãããŠããã®æäœç£ç现èãšã¯ããã
ã®ãªã³ãçïŒåã¯ïŒ¢çŽ°èïŒã§ãã€ãŠãæäœãåæ³
ããŠããåã¯åæ³ããèœåãæã€ã现èãããã
ããã¯èŸèããªã³ãç¯ãæ«æ¢¢è¡ã骚é«ãææ¡ãã¢
ããã€ãçã®çŽ°èã®äžã«å«ãŸããŠãããæ¬çºæã®
ç®çã®ããã«ã¯ããããªããœãŒã¹ã®ãªã³ãçã§ã
çšããããšãã§ãããã奜ãŸããã®ã¯ææ¡è ºåã¯
èŸèããæ¡åããããã®ã§ããã ããŠã¹ã®ããšããŒã现èãšããŠã¯ãïŒâã¢ã¶ã°
ã¢ãã³èæ§æ ªãçšããã®ãæå©ã§ãããå ¬ç¥ã®ã
ã®ãšããŠã¯ãBALBïŒïŒ£ããŠã¹ã®P3âX63â
Ag8ãP3âX63âAg8âU1ãP3âNS1ïŒïŒâ
Ag4âïŒãP3âX63âAg8âïŒïŒïŒïŒïŒãSP2ïŒ
âAg14ãFOãMPC11â45.6TG1.7ãªã©ãã
ãã æ¬çºæã«ãããŠã¯ããŸããæåã§ããç¹å®ã®
LPSãæããç·è¿èãéžã¶ã次ã«ããã®ãªã³ãç
ãææ¡è ºããªã³ãç¯ãèŸèåã³æ«æ¢¢è¡çã®çµç¹ã
ãã¢ããã¯ãªã¢ãŒã»ã«ïŒåæ žçŽ°èïŒãšããŠèª¿æŽã
ãããã®ã¢ããã¯ãªã¢ãŒã»ã«ãïŒæ¥ãïŒæ¥ãããŒ
ã¯ãŠã€ãŒããã€ããžãšã³çã®ãã€ããžãšã³ã®æ·»å
ãããã¯ç¡æ·»å ã®æ¡ä»¶äžã§ãïŒïŒ CO2ã€ã³ããŠã
ãŒã¿ãŒã§å¹é€ãããã®å¹é€äžæž 液äžã®æäœããå
èšç·è¿èãåºå®ãããã¬ãŒãã§é µçŽ æäœæ³ã«ãã
枬å®ããæãŸããã¢ãã¯ãªã¢ãŒã»ã«ãå«ãçµç¹ã
éžã¶ã次ãã§ããã®çµç¹ã®ãªã³ãçãšããšããŒã
现èãèåããããã€ããªããŒãã®ç°è³ªéèœã圢
æãããã现èèåã¯å ¬ç¥ã®æ¹æ³ã§è¡ãªãããšã
ã§ãããäŸãã°ãæäœç£ç现èãšããšããŒã现è
èã10ïŒïŒãïŒïŒ10ã奜ãŸããã¯ïŒïŒïŒãïŒïŒïŒ
ã®æ¯çã§æ··åããé©åœãªçŽ°èèåçšæº¶æ¶²ãäŸãã°
çŽ35ïŒ ããªãšãã¬ã³ã°ãªã³ãŒã«ïŒååé1000ã
6000çšåºŠïŒããã³çŽ7.5ïŒ ãžã¡ãã«ã¹ã«ããã·ã
ãå«ãRPMI1640ãå ããŠã宀枩ã37âã§ïŒãæ°
åéæ¹æãããã®åŸ10ïŒ FCSå RPMI1640ã§åŸã
ã«åžéããæŽæµã®åŸHATïŒããããµã³ãã³âã¢
ãããããªã³âãããžã³ïŒéžæå¹é€æ¶²ã«ãŠçŽ°èæ¿
床ãïŒãïŒÃ105åïŒmlãšãªãããã«èª¿æŽããã
ããã0.2mlãã€ãäŸãã°96ç©Žãã¬ãŒãã«å泚ãã
ïŒïŒ CO2ãå«ã空æ°äžã§35ã38âã§ïŒãïŒæéå¹
é€ãããHATå¹é€æ¶²äžã§ã¯ãã€ããªããŒãã®ã¿
ãååšããïŒâã¢ã¶ã°ã¢ãã³èæ§ã®ããšããŒã现
èåã³ããšããŒãå士ã®èå现èã¯çåãåŸãªã
ïŒæªèåã®æäœç£ç现èã¯æ°æ¥ã§æ»æ» ãããïŒæ¬¡
ã«ããã®ãã€ããªããŒãéèœãããç·è¿èLPSã«
察ãç¹ç°çãªããã¢ãã¯ããŒãã«æäœãåæ³ãã
ãã®ã ãéžå¥ããããã®éžå¥å·¥çšã¹ã¯ãªãŒãã³ã°
ã¯ãç°ãªããã€ããªããŒãããç£çãããããã¢
ãã¯ããŒãã«æäœããç®çãšããè¡æž åãæãã
ç·è¿èåã¯ç·è¿èLPSãåºå®ãããã¬ãŒããçšã
ãŠãé µçŽ æäœæ³ãçšããŠè¡ãªãäºãã§ãããå šãŠ
ã®ç·è¿èã®è¡æž åã«åå¿ããããã¢ãã¯ããŒãã«
æäœãåŸãçºã«ã¯ã16çš®é¡ã®ç°ãè¡æž åã®ç·è¿è
ã䜿çšããªããŠã¯ãªããªãããããã®ç·è¿èã¯ã
ã¢ã¡ãªã«ã³ã»ã¿ã€ãã«ã«ãã€ãŒã³ã¬ã¯ã·ãšã³
ïŒATCCïŒããå ¥æã§ããã ç®çãšããç·è¿èã«å¯Ÿããã¢ãã¯ããŒãã«æäœ
ãåæ³ãããã€ããªããŒãã¯ã次ã«ã¯ããŒãã³ã°
ã«ããã¯ããŒã³å现èã«ããªããŠã¯ãªããªããã
ã®å·¥çšã¯ãå ·äœçã«ã¯è»å¯å€©æ³ãçšãè¡ãäºãã§
ãããçŽïŒãïŒé±éåŸãè»å¯å€©äžã§çè²ããã³ã
ããŒãæŸããåã³é µçŽ æäœæ³ã§ç·è¿èã«å¯Ÿããæ
äœæŽ»æ§ã調ã¹éžå¥ãããéžå¥ãããã€ããªããŒã
ãå¹é€ããŠãææã®LPSç¹ç°çããã¢ãã¯ããŒã
ã«æäœãçæãããã ã¢ãã¯ããŒãã«æäœãåŸãããã®ããäžã€ã®æ¹
æ³ã¯ãããã®æç·è¿èæäœç£ç现èããšãã¹ã¿ã€
ã³ã»ããŒã»ãŠã€ã«ã¹ïŒEpsteinâBarr Virusã以
äžïŒ¥âãŠã€ã«ã¹ãšç¥ç§°ããïŒãææãããŠåœ¢è³ª
転æ现èãäœæãã該圢質転æ现èåã³ïŒåã¯ã
ãã«ç±æ¥ãã现èæ ªãå¹é€ããå¹é€ç©ããç·è¿è
ã®ãªãå€ç³ã«çµåããæ§è³ªãæããããã¢ãã¯ã
ãŒãã«æäœãæ¡åããæ¹æ³ã§ããã âãŠã€ã«ã¹ã¯ãããŒããããªã³ãè «ã錻åœ
é ã¬ã³ã®åå ãŠã€ã«ã¹ãšãããŠããããã«ãã¹ãŠ
ã€ã«ã¹çŸ€ã«å±ãããŠã€ã«ã¹ã§ãããåèšãšåæ§ãª
ããã®ãªã³ãçã®ã¢ããã¯ãªã¢ãŒã»ã«ãâãŠ
ã€ã«ã¹ã«ææãããçŽïŒãïŒé±éãïŒïŒ CO2ã€ã³
ããŠããŒã¿ã§å¹é€ããå€ãã®ç°è³ªéèœããæã圢
質転æ现èïŒãã©ã³ã¹ããªãŒã ãã»ã«ïŒã圢æã
ããã次ã«ããã®åœ¢è³ªè»¢æ现èãããç·è¿èLPS
ã«å¯Ÿãç¹ç°çãªããã¢ãã¯ããŒãã«æäœãåæ³ã
ããã®ã ãããåèšãšåæ§ãªæ¹æ³ã§éžå¥ãããã
ããŠãåèšãšåæ§ã«ããŠãã¯ããŒã³åããã圢質
転æ现èãåŸãããšãã§ããã 次ã«ãæ¬çºæã«ãããŠã¯ãéžæãããã€ããªã
ãŒãåã¯åœ¢è³ªè»¢æ现èãå¹é€ããŠãææã®ç¹ç°ç
ããã¢ãã¯ããŒãã«æäœãçæãããã ã¯ããŒãã³ã°ã«ãã€ãŠéžæããããæç·è¿èã
ãæäœãç£çããããŠã¹âãããã€ããªããŒãå
ã¯ãã圢質転æ现èã¯åçµããŠä¿åããããšãã§
ãããŸãããããé©åœãªæ¹æ³ã§å€§éã«å¹é€ããã
ãšãã§ããããããŠãå¹é€äžæž ããç·è¿èLPSã«
ç¹ç°çã«çµåããã¢ãã¯ããŒãã«ãªæç·è¿èãã
æäœãåŸãããšãã§ããããŸããããã现èãå
ç©ã«ç§»æ€ããŠè «çåãããã®è ¹æ°Žãè¡æž ããæç·
è¿èããæäœãåŸãããšãã§ãããæç·è¿èãã
æäœã®ç²Ÿè£œã¯ãã¢ãã¯ããŒãã«æäœãçšããã¢ã
ã€ããã€ã¯ãããã°ã©ãã€ãŒçã®æ¹æ³ã«ãã€ãŠè¡
ãªãããã (ã) äœçš æç·è¿èLPSããã¢ãã¯ããŒãã«æäœã¯ãç·è¿
èLPSã«ç¹ç°çã«çµåããŠè£äœã«ããç·è¿èãå
ç«æº¶èãããããŸããç·è¿èææããŠã¹ã¢ãã«å®
éšã®ç³»ã§ããŠã¹ãææããé²åŸ¡ããããšãã§ã
ãã æ¬çºæã®ããã¢ãã¯ããŒãã«æäœã¯ãäºãã«æ··
åãããç·è¿èã®å šãŠã®16çš®ã®è¡æž åã«çµåãã
ãäºãã§ãããæç·è¿èLPSããã¢ãã¯ããŒãã«
æäœã¯ãè¡æž åç¹ç°çã«çµåããææã¢ãã«å®éš
ç³»ã§ææé²åŸ¡èœãçºæ®ãããããªãã¡ãããè¡æž
åã«ç¹ç°çãªããã¢ãã¯ããŒãã«æäœã¯ãåãè¡
æž åã®ç·è¿èã«ã¯ã100ïŒ çµåãåŸãããç°ãè¡
æž åã®ç·è¿èã«ã¯å šãçµåã§ããªããåŸã€ãŠãå
ããã¢ãã¯ããŒãã«æäœãæ··ãåããäºã«ããã
çŸåšããã€ãŠããå šãŠã®è¡æž åã®ç·è¿èã«çµåã
ãããäºãã§ããã (ã) åé¡ç¹ã解決ããããã®æ段ïŒãã®äºïŒ æ¬çºæã®ç·è¿èã®ãªãå€ç³ãèªèããæ§è³ªãæ
ããæç·è¿èããã¢ãã¯ããŒãã«æäœã¯ãä»ã®é
åžžã®å»è¬å©å€ãšå ±ã«å»è¬è£œå€ãšããããšãã§ãã
ããã¯ããåã³åç©ã®ç·è¿èææçã®æ²»çå€ãšã
ãŠçšãããããããã補å€ã«ãããŠã¯ãå šãŠã®è¡
æž åã«å¯Ÿå¿ããã¢ãã¯ããŒãã«æäœãæ··åããã
ãšã¯å¿ ãããå¿ èŠã§ã¯ãªããå°ãªããšãè¡æž åã
ïŒåãïŒåãïŒåãïŒååã³10åã®ç·è¿èã«å¯Ÿã
ãæç·è¿èããã¢ãã¯ããŒãã«æäœãå«ã補å€ãš
ããã°ãç·è¿èææçã®70ïŒ ä»¥äžãæ²»çããããš
ãã§ããã æ¬çºæã®ããã¢ãã¯ããŒãã«æäœã®æäžæ¹æ³ã¯
åã ã®ç¶æ³ããšãã°åŠçœ®ãã¹ãç·è¿èææçã®ç¶
æ³ã«ããå€åããåæ§ã«æäžéåã³æäžã®é »åºŠã«
å¿ããŠå€åãããäžè¬ã«ãæäœã¯æäžåã«éæ¯æ§
ã®å»è¬äžèš±å®¹ãåŸããã€ãªã¢ç©è³ªãäŸãã°ãéåžž
ã®é£å¡©æ°Žãšæ··åãããä»»æã®å»çäžé©åœãªæ¹æ³ã
äŸãã°ãéèæäžã«ãã€ãŠæäžããããäžè¬ã«ã
æäœã¯ãã€ãªã¢äžã«çŽ0.5ÎŒïœæäœïŒmlã500ÎŒïœæ
äœïŒmlã®æ¿åºŠã§ååšããããïŒåã®æäžããæäœ
ã®éã¯ãäžè¬ã«äœéïŒKgå€ã10ÎŒïœã10mgã®æäœ
ã®ç¯å²ã§ãããæãå Žåã«ã¯ãïŒå以äžã®äžé£ã®
æäžãå¿ èŠãšãããã (ã) å®æœäŸ 以äžãå®æœäŸã«ããæ¬çºæã詳述ããã å®æœäŸ ïŒ (1) æç·è¿èæäœç£ç现èã®éžå¥ ïŒäººã®ææ¡çæ£è ããïŒãããã®ææ¡è ºã
åŸããããããã¢ã€ã³ãŒã«ããã¯ãçšãã¢ãã
ã¯ãªã¢ãŒã»ã«ã調補ããã现èæ¿åºŠãïŒÃ
106ïŒmlã«ãªãæ§ã«ãã¢ããã¯ãªã¢ãŒã»ã«ãå¹
é€æ¶²ïŒ¡ïŒRPMI1640ïŒ10ïŒ èå çè¡æž ïŒ2mMã°
ã«ã¿ãã³ïŒ1mMãã«ãã³é žïŒ0.02mgïŒmlã»ãª
ã³ïŒ80ÎŒïœïŒmlã²ã³ã¿ãã€ã·ã³ïŒã«æµ®éããã
ããã«ãããŒã¯ãŠã€ãŒããã€ããžãšã³
ïŒPWMïŒã20ÎŒïœïŒmlã«ãªãæ§ã«å ããããã®
è©Šæã200ÎŒã¥ã€å¹é€ãã¬ãŒãã«å ¥ããCO2ã€
ã³ããŠããŒã¿ïŒïŒïŒ CO2ïŒã§ïŒãïŒæ¥å¹é€ã
ãããã®åŸãããããã®å¹é€äžæž 液100ÎŒã
ç·è¿èãã³ãŒããããã¬ãŒãã«ç§»ããé µçŽ æäœ
æ³ã§æž¬å®ãè¡ã€ããšãããïŒãããã ã匷ãæ
ç·è¿èæäœãç£çããŠããããã®ãããã®ã¢ã
ãã¯ãªã¢ãŒã»ã«ããããŠã¹ããšããŒã现èP3
â 63âAg8âUIïŒä»¥äžP3UIãšç¥èšããïŒãš
ã®çŽ°èèåã«çšããã (2) 现èèå åãã€ãŠP3UIãå¹é€æ¶²ïŒ¡äžã§å¹é€ããŠãã
ãã䜿çšæã®çŽ°èæ¿åºŠã¯ïŒÃ105åïŒmlã§ãã€
ããäžèšã®æç·è¿èæäœç£çãããããŠããæ
æ¡è ºãããã®ãªã³ãçãšP3UIãããããã
å¥ã ã«ç¡è¡æž RPMI1640ã§ïŒåæŽæµãããã
ãŠããªã³ãçãšïŒÃ106åã®P3UIãšãè©Šéšç®¡ã®
äžã§äžç·ã«ãã次ãã§1500rpmã§ïŒåéé å¿
ããäžæž ãæšãŠãã现èãã¬ããããè©Šéšç®¡ã«
ãããããšã«ãã€ãŠãããåæ£ããããããã«
0.5mlã®ããªãšãã¬ã³ã°ãªã³ãŒã«æ¶²
ïŒRPMI1640 75mlÃããªãšãã¬ã³ã°ãªã³ãŒã«
1500 3.5mlïŒãžã¡ãã«ã¹ã«ãããµã€ã0.75mlïŒ
ïŒPEG液ãšç¥èšããïŒãå ããŠã现èãããã
ãã«æµ®éããããïŒååŸã«0.5mlã®RPMI1640
ãå ããããã«ïŒååŸã«ïŒmlRPMIãããã«ïŒ
ååŸã«ïŒmlã®HATå¹é€æ¶²ïŒRPMI1640ïŒ20ïŒ
èå çè¡æž ïŒ80ÎŒïœïŒmlã²ã³ã¿ãã€ã³ã·ã³ïŒ
95ÎŒMããããµã³ãã³ïŒ0.4ÎŒMã¢ãããããªã³
ïŒ1.6ÎŒMãããžã³ïŒãããã«ïŒååŸã«ã¯ïŒmlã®
HATå¹é€æ¶²ãå ãããæåŸã«ãHATå¹é€æ¶²
ã§25ml现èæµ®é液ãšããããããå¹é€ãã¬ãŒã
ïŒ96ç©ŽïŒïŒæã«èããŠã37âãïŒïŒ CO2å«æ空
æ°äžã§å¹é€ãããäžé±éæ¯ã«åéã®å¹é€æ¶²ãæ°
ããHTå¹é€æ¶²ïŒHATãããé€å»ãããã®ïŒ
ã§äº€æããŠãããã€ããªããŒããåŸãã (3) ã¯ããŒãã³ã°åã³å¹é€ åŸããããã€ããªããŒãã®äžæž ããã«ããªã³
æ»æ» ç·è¿èãã³ãŒãã€ã³ã°ãããã¬ãŒããçšã
ãŠELISAæ³ã§æž¬å®ãè¡ã€ãçµæãç·è¿èè¡æž
åHommaã®type5ã«çµåããããã¢ãã¯ããŒ
ãã«æäœP3ãåŸããããã§ãP3ãç£çããã
ã€ããªããŒãããïŒåéçåžéæ³ã«ããã¯ããŒ
ãã³ã°ãè¡ãïŒ96ç©Žãã¬ãŒãïŒæïŒæçµçã«
P3D9ãšããããã¢ãã¯ããŒãã«æäœïŒIgGã
λïŒãç£çããããŠã¹âãããã€ããªããŒãã
åŸãã æ¬ãã€ããªããŒãããç¡è¡æž å¹å°RDFïŒ
TESå¹å°ïŒProc.Natl.Acad.Sci.USA vol.79ã
1158â1162åç §ïŒïŒã§å¹é€ãè¡ããP3D9ã
å«ãå¹é€æ¶²ãéå€æ¿ŸéèPM30ïŒã¢ãã³ã³ç€Ÿè£œïŒ
ãçšããŠæ¿çž®ãè¡ãã30mlãšããããããŠ
DEAEâSephacelã§ã«ã©ã ã¯ããããè¡ãã
P3D9ã粟補ã12mgãåŸãã (4) ã¢ãã¯ããŒãã«æäœã®ææé²åŸ¡å¹æ P3D9ã®ææé²åŸ¡å¹æã調ã¹ããããç·è¿è
èšåºåé¢æ ªïŒ®âïŒåã³97ãéžã°ãããâïŒã®
è¡æž åã¯ãHomma type5ã§ã97ã®ããã¯
Homma type7ã§ãã€ãã ïŒé±ä»€ã®ICRããŠã¹ïŒéãäœé16ã20ïœïŒã«
ïŒåã¯4LD50ã®ïŒ®âïŒæ ªåã¯97æ ªãè ¹è ã«æäž
ãããïŒäžçŸ€10å¹ïŒãããŠãïŒæéåŸã«ã10ÎŒ
ïœåã¯1ÎŒïœã®P3D9ãè ¹è å ã«æäžãããããž
ãã€ãã³ã³ãããŒã«ãšããŠãããè¡æž ãã粟補
ããIgGãè ¹è å ã«æäžããããã¬ãã€ãã³ã³
ãããŒã«ãšããŠãççé£å¡©æ°Žãåéæäžããã
ïŒæ¥é芳å¯åŸã®çµæã第ïŒè¡šã«ç€ºããã
ãè¡šã
ïŒ çåæ°ïŒæž¬å®æ°ã瀺ã
第ïŒè¡šãããæ¬çºæã®ããã¢ãã¯ããŒãã«æ
äœP3D9ã¯ãç·è¿èã®ïŒ®âïŒæ ªïŒHomma
type5ïŒã«ç¹ç°çãªææé²åŸ¡å¹æã瀺ãããšã
ãããã å®æœäŸ ïŒ (1) ããã®èŸçŽ°èãçšãã以å€ã¯ãå®æœäŸïŒã®å Ž
åãšåæ§ã«ããŠãæäœç£ç现èã®éžå¥åã³çŽ°è
èåãè¡ãªã€ããåŸããããã€ããªããŒãã®äž
æž ãããã«ããªã³æ»æ» ç·è¿èãã³ãŒãã€ã³ã°ã
ããã¬ãŒããçšããŠELISAæ³ã§æž¬å®ãè¡ã€ã
çµæãç·è¿èè¡æž åHomma type2ãHomma
type7ãHomma type13ã®ããããšãçµåãã
ããã¢ãã¯ããŒãã«æäœB8ãåŸããB8ãç£ç
ãããã€ããªããŒãããïŒåéçåžéæ³ã«ãã
ã¯ããŒãã³ã°ãè¡ããB8E2ãšããããã¢ãã¯
ããŒãã«æäœïŒIgGãλïŒãç£çããããŠã¹â
ãããã€ããªããŒããåŸãã æ¬ãã€ããªããŒããã10ïŒ FCSRPMI16401
ã§å¹é€ãè¡ããB8E2ãç¡«å®æ²æŸ±ïŒ50ïŒ é£œåïŒ
ã«ããååãããDEAEâSephacelã§éšå粟
補ãè¡ã€ããããIgéã¯ãäžå å¹³æ¿å ç«æ¡æ£æ³
ïŒSRIDïŒã«ããå®éãè¡ããïŒmgã®B8E2ãå«
ãæäœæº¶æ¶²ãåŸããæ¬ã¢ãã¯ããŒãã«æäœã¯ã
Homma type2ãHomma type7åã³Homma
type13ãããJohnson and PerryïŒCan.J.
microbiol 1976 vol22ïŒ29â34ã®æ¹æ³ã«ããæœ
åºããLPSåã³ãã®ç±åŠçïŒ100ââ30åïŒ
LPSãã³ãŒãã€ã³ã°ãããã¬ãŒããçšãã
ELISAæ³ã§ãããããã®LPSã«çµåããäºã
確ããããLPSãèªèããã¢ãã¯ããŒãã«æäœ
ã§ããäºãããã€ãã (2) ã¢ãã¯ããŒãã«æäœã®ææé²åŸ¡å¹æ B8E2ã®ææé²åŸ¡å¹æãå®æœäŸïŒã®å Žåãšå š
ãåæ§ã«ããŠãç·è¿èèšåºåé¢æ ªïŒ®âïŒ
ïŒtype5ïŒãš97ïŒtype7ïŒãçšããŠè¡ãªããçµæã
第ïŒè¡šã«ç€ºããã
第ïŒè¡šãããæ¬çºæã®ããã¢ãã¯ããŒãã«æ
äœP3D9ã¯ãç·è¿èã®ïŒ®âïŒæ ªïŒHomma
type5ïŒã«ç¹ç°çãªææé²åŸ¡å¹æã瀺ãããšã
ãããã å®æœäŸ ïŒ (1) ããã®èŸçŽ°èãçšãã以å€ã¯ãå®æœäŸïŒã®å Ž
åãšåæ§ã«ããŠãæäœç£ç现èã®éžå¥åã³çŽ°è
èåãè¡ãªã€ããåŸããããã€ããªããŒãã®äž
æž ãããã«ããªã³æ»æ» ç·è¿èãã³ãŒãã€ã³ã°ã
ããã¬ãŒããçšããŠELISAæ³ã§æž¬å®ãè¡ã€ã
çµæãç·è¿èè¡æž åHomma type2ãHomma
type7ãHomma type13ã®ããããšãçµåãã
ããã¢ãã¯ããŒãã«æäœB8ãåŸããB8ãç£ç
ãããã€ããªããŒãããïŒåéçåžéæ³ã«ãã
ã¯ããŒãã³ã°ãè¡ããB8E2ãšããããã¢ãã¯
ããŒãã«æäœïŒIgGãλïŒãç£çããããŠã¹â
ãããã€ããªããŒããåŸãã æ¬ãã€ããªããŒããã10ïŒ FCSRPMI16401
ã§å¹é€ãè¡ããB8E2ãç¡«å®æ²æŸ±ïŒ50ïŒ é£œåïŒ
ã«ããååãããDEAEâSephacelã§éšå粟
補ãè¡ã€ããããIgéã¯ãäžå å¹³æ¿å ç«æ¡æ£æ³
ïŒSRIDïŒã«ããå®éãè¡ããïŒmgã®B8E2ãå«
ãæäœæº¶æ¶²ãåŸããæ¬ã¢ãã¯ããŒãã«æäœã¯ã
Homma type2ãHomma type7åã³Homma
type13ãããJohnson and PerryïŒCan.J.
microbiol 1976 vol22ïŒ29â34ã®æ¹æ³ã«ããæœ
åºããLPSåã³ãã®ç±åŠçïŒ100ââ30åïŒ
LPSãã³ãŒãã€ã³ã°ãããã¬ãŒããçšãã
ELISAæ³ã§ãããããã®LPSã«çµåããäºã
確ããããLPSãèªèããã¢ãã¯ããŒãã«æäœ
ã§ããäºãããã€ãã (2) ã¢ãã¯ããŒãã«æäœã®ææé²åŸ¡å¹æ B8E2ã®ææé²åŸ¡å¹æãå®æœäŸïŒã®å Žåãšå š
ãåæ§ã«ããŠãç·è¿èèšåºåé¢æ ªïŒ®âïŒ
ïŒtype5ïŒãš97ïŒtype7ïŒãçšããŠè¡ãªããçµæã
第ïŒè¡šã«ç€ºããã
ãè¡šã
ãè¡šã
第ïŒè¡šãããæ¬çºæã®ããã¢ãã¯ããŒãã«æ
äœB8E2ã¯ãç·è¿èã®97æ ªïŒtype7ïŒã«ç¹ç°çã«
ææé²åŸ¡å¹æãåããŠããããšããããã å®æœäŸ ïŒ ããã®ææ¡è ºçŽ°èãçšããå®æœäŸïŒã®å Žååæ§
ã«ããŠãæäœç£ç现èã®éžå¥åã³çŽ°èèåãè¡ãª
ã€ããåŸããããã€ããªããŒãã®äžæž ãããã«ã
ãªã³æ»æ» ç·è¿èãã³ãŒãã€ã³ã°ãããã¬ãŒããçš
ããŠELISAæ³ã§æž¬å®ãè¡ã€ãçµæãç·è¿èè¡æž
åHomma type1ã«çµåãã31âïŒãåtype7ã«
çµåãã31âïŒãåtype8ã«çµåãã31âïŒãå
ã³åtype10ã«çµåãã31â12ãåŸãããããã®ã
ãã¢ãã¯ããŒãã«æäœãç£çãããã€ããªããŒã
ããéçåžéæ³åã³è»å¯å€©æ³ã«ããïŒåã¯ããŒã
ã³ã°ãè¡ãïŒ96ç©Žãã¬ãŒãïŒæïŒãããã31âïŒ
â2Aã31âïŒâ5Gã31âïŒâF4ã31â12âH3
ã®ããåIgGãç£çãããã€ããªããŒããåŸãã ããããã€ããªããŒããå®æœäŸïŒãšåæ§ã®æ¹æ³
ã§å¹é€ããéšå粟補ãè¡ããããããã®ã¢ãã¯ã
ãŒãã«æäœãåå¿ããæåéšäœã決å®ãã¹ãã
LPSåã³ç±åŠçïŒ100âÃ2hrïŒLPSãšã®çµåæ§ã
ELISAã«ããå®æœããããã®çµæã第ïŒè¡šã«ç€º
ãããïŒåå¿æéã¯60åïŒã
äœB8E2ã¯ãç·è¿èã®97æ ªïŒtype7ïŒã«ç¹ç°çã«
ææé²åŸ¡å¹æãåããŠããããšããããã å®æœäŸ ïŒ ããã®ææ¡è ºçŽ°èãçšããå®æœäŸïŒã®å Žååæ§
ã«ããŠãæäœç£ç现èã®éžå¥åã³çŽ°èèåãè¡ãª
ã€ããåŸããããã€ããªããŒãã®äžæž ãããã«ã
ãªã³æ»æ» ç·è¿èãã³ãŒãã€ã³ã°ãããã¬ãŒããçš
ããŠELISAæ³ã§æž¬å®ãè¡ã€ãçµæãç·è¿èè¡æž
åHomma type1ã«çµåãã31âïŒãåtype7ã«
çµåãã31âïŒãåtype8ã«çµåãã31âïŒãå
ã³åtype10ã«çµåãã31â12ãåŸãããããã®ã
ãã¢ãã¯ããŒãã«æäœãç£çãããã€ããªããŒã
ããéçåžéæ³åã³è»å¯å€©æ³ã«ããïŒåã¯ããŒã
ã³ã°ãè¡ãïŒ96ç©Žãã¬ãŒãïŒæïŒãããã31âïŒ
â2Aã31âïŒâ5Gã31âïŒâF4ã31â12âH3
ã®ããåIgGãç£çãããã€ããªããŒããåŸãã ããããã€ããªããŒããå®æœäŸïŒãšåæ§ã®æ¹æ³
ã§å¹é€ããéšå粟補ãè¡ããããããã®ã¢ãã¯ã
ãŒãã«æäœãåå¿ããæåéšäœã決å®ãã¹ãã
LPSåã³ç±åŠçïŒ100âÃ2hrïŒLPSãšã®çµåæ§ã
ELISAã«ããå®æœããããã®çµæã第ïŒè¡šã«ç€º
ãããïŒåå¿æéã¯60åïŒã
ãè¡šã
第ïŒè¡šãããããã¢ãã¯ããŒãã«æäœã¯ããã
ãç¹ç°ãªLPSã«çµåããŠããããšããããã å®æœäŸ ïŒ å®æœäŸïŒãïŒã§åŸãããããŠã¹âãããã€ããª
ããŒããç£çããããã¢ãã¯ããŒãã«æäœã®ãç·
è¿èã·ãŠãŒãã¢ãã¹å±ã®èæ ªåã³è žå 现èç§ã°ã©
ã éœæ§ã®èæ ªã«å¯Ÿãããçµåã¹ãã¯ãã©ã ã
ELISAæ³ã§æž¬å®ããããã®çµæã第ïŒè¡šã«ç€ºã
ãã
ãç¹ç°ãªLPSã«çµåããŠããããšããããã å®æœäŸ ïŒ å®æœäŸïŒãïŒã§åŸãããããŠã¹âãããã€ããª
ããŒããç£çããããã¢ãã¯ããŒãã«æäœã®ãç·
è¿èã·ãŠãŒãã¢ãã¹å±ã®èæ ªåã³è žå 现èç§ã°ã©
ã éœæ§ã®èæ ªã«å¯Ÿãããçµåã¹ãã¯ãã©ã ã
ELISAæ³ã§æž¬å®ããããã®çµæã第ïŒè¡šã«ç€ºã
ãã
ãè¡šã
第ïŒè¡šãããããã¢ãã¯ããŒãã«æäœã¯ç·è¿è
è¡æž åç¹ç°æ§ãæããããšããããã å®æœäŸ ïŒ æç·è¿èããã¢ãã¯ããŒãã«æäœP3D9ã
B8E2ã31âïŒâ2Aã31âïŒâ5Gã31âïŒâF4ã
31â12âH3ã®åäžè¡æž åã®ç·è¿èã«å¯Ÿããçµå
æ§ãELISAæ³ã§æž¬å®ããããã®çµæã第ïŒè¡šã«
瀺ãããè¡šããããããã®ã¢ãã¯ããŒãã«æäœ
ããåäžè¡æž åã®ç·è¿èãš100ïŒ å®å šã«åå¿ããŠ
ããããšããããã
è¡æž åç¹ç°æ§ãæããããšããããã å®æœäŸ ïŒ æç·è¿èããã¢ãã¯ããŒãã«æäœP3D9ã
B8E2ã31âïŒâ2Aã31âïŒâ5Gã31âïŒâF4ã
31â12âH3ã®åäžè¡æž åã®ç·è¿èã«å¯Ÿããçµå
æ§ãELISAæ³ã§æž¬å®ããããã®çµæã第ïŒè¡šã«
瀺ãããè¡šããããããã®ã¢ãã¯ããŒãã«æäœ
ããåäžè¡æž åã®ç·è¿èãš100ïŒ å®å šã«åå¿ããŠ
ããããšããããã
ãè¡šã
ãè¡šã
å®æœäŸ ïŒ
10HÎŒïœïŒmlæ¿åºŠã®P3D9ã®0.5mlãïŒÃ
106CFUïŒmlæ¿åºŠã®ç·è¿èâïŒïŒtype5ïŒã®0.5ml
åã³ïŒÃ106CFUïŒmlæ¿åºŠç·è¿èâ64ïŒtype6ïŒ
ã®0.5mlãšããããæ··ãåãã該åœèæ ªã§åžåã
è¡ã€ãã¢ã«ã¢ããçè£äœã0.2mlå ãã37âã§å¹
é€ããããããŠã30åãïŒæéãïŒæéæ¯ã«0.3
mlã¥ã€ãµã³ããªã³ã°ããHIAå¹å°äžã§çè²ãã
ãŠã³ãããŒæ°ã枬å®ãããçµæã第ïŒè¡šã«ç€ºã
ãã
106CFUïŒmlæ¿åºŠã®ç·è¿èâïŒïŒtype5ïŒã®0.5ml
åã³ïŒÃ106CFUïŒmlæ¿åºŠç·è¿èâ64ïŒtype6ïŒ
ã®0.5mlãšããããæ··ãåãã該åœèæ ªã§åžåã
è¡ã€ãã¢ã«ã¢ããçè£äœã0.2mlå ãã37âã§å¹
é€ããããããŠã30åãïŒæéãïŒæéæ¯ã«0.3
mlã¥ã€ãµã³ããªã³ã°ããHIAå¹å°äžã§çè²ãã
ãŠã³ãããŒæ°ã枬å®ãããçµæã第ïŒè¡šã«ç€ºã
ãã
ãè¡šã
P3D9ã¯type5ã®ïŒ®âïŒã®ã¿ãéžæçã«æ»æããŠ
ããããšããããã å®æœäŸ ïŒ ããã®ææ¡è ºçŽ°èãçšããŠãå®æœäŸïŒã®å Žåãš
åæ§ã«æäœç£ç现èã®éžå¥åã³çŽ°èèåãè¡ã€
ããåŸããããã€ããªããŒãã®äžæž ããã«ããªã³
æ»æ» ç·è¿èãã³ãŒãã€ã³ã°ãããã¬ãŒããçšã
ãŠã第ïŒæ¬¡æäœãã€ã®æããIgMæäœïŒã¢ã«ã«ãª
ããªã¹ãã¢ã¿ãŒãŒæšèïŒãšããŠãELISAãè¡ã€
ãçµæãè¡æž åãHomma type5ãtype7ãtype8
ã«åå¿ããIgMåããã¢ãã¯ããŒãã«æäœãåŸã
ããããããã®ããã¢ãã¯ããŒãã«æäœãç£çã
ããã€ããªããŒãããéçåžéæ³åã³è»å¯å€©æ³ã«
ããïŒåã¯ããŒãã³ã°ãè¡ããããããã313â
ïœã313âïœã313âïœã®ããã¢ãã¯ããŒãã«æäœ
ãç£çãããã€ããªããŒããåŸãããã®åŸãå®æœ
äŸïŒãšåæ§ã®æ¹æ³ã«ããéšå粟補ãè¡ããããã
ãã®ã¢ãã¯ããŒãã«æäœãåå¿ããæåéšäœã決
å®ãã¹ããLPSåã³ç±åŠçLPSãšã®çµåæ§ã
ELISAæ³ã«ããæ€èšããããã®çµæã第ïŒè¡šã«
瀺ããã
ããããšããããã å®æœäŸ ïŒ ããã®ææ¡è ºçŽ°èãçšããŠãå®æœäŸïŒã®å Žåãš
åæ§ã«æäœç£ç现èã®éžå¥åã³çŽ°èèåãè¡ã€
ããåŸããããã€ããªããŒãã®äžæž ããã«ããªã³
æ»æ» ç·è¿èãã³ãŒãã€ã³ã°ãããã¬ãŒããçšã
ãŠã第ïŒæ¬¡æäœãã€ã®æããIgMæäœïŒã¢ã«ã«ãª
ããªã¹ãã¢ã¿ãŒãŒæšèïŒãšããŠãELISAãè¡ã€
ãçµæãè¡æž åãHomma type5ãtype7ãtype8
ã«åå¿ããIgMåããã¢ãã¯ããŒãã«æäœãåŸã
ããããããã®ããã¢ãã¯ããŒãã«æäœãç£çã
ããã€ããªããŒãããéçåžéæ³åã³è»å¯å€©æ³ã«
ããïŒåã¯ããŒãã³ã°ãè¡ããããããã313â
ïœã313âïœã313âïœã®ããã¢ãã¯ããŒãã«æäœ
ãç£çãããã€ããªããŒããåŸãããã®åŸãå®æœ
äŸïŒãšåæ§ã®æ¹æ³ã«ããéšå粟補ãè¡ããããã
ãã®ã¢ãã¯ããŒãã«æäœãåå¿ããæåéšäœã決
å®ãã¹ããLPSåã³ç±åŠçLPSãšã®çµåæ§ã
ELISAæ³ã«ããæ€èšããããã®çµæã第ïŒè¡šã«
瀺ããã
ãè¡šã
å®æœäŸ ïŒ
ç·è¿èæè¡çæ£è
ã®æ«æ¢¢ãªã³ãçãçšããŠå®æœ
äŸïŒã®å Žåãšåæ§ã«çŽ°èèåãè¡ãªããã¹ã¯ãªãŒ
ãã³ã°ã«ããHomma type5ã«ã®ã¿åå¿ãããã
IgAã¢ãã¯ããŒãã«æäœãç£çãããã€ããªããŒ
ã4H11D10ãåŸãã 4H11D10ã¯è¡æž åãtype5ã®ïŒã€ã®æ ªã«ã¯ãã¹
ãŠåå¿ãããçµæã¯ç¬¬ïŒè¡šã«ç€ºããã
äŸïŒã®å Žåãšåæ§ã«çŽ°èèåãè¡ãªããã¹ã¯ãªãŒ
ãã³ã°ã«ããHomma type5ã«ã®ã¿åå¿ãããã
IgAã¢ãã¯ããŒãã«æäœãç£çãããã€ããªããŒ
ã4H11D10ãåŸãã 4H11D10ã¯è¡æž åãtype5ã®ïŒã€ã®æ ªã«ã¯ãã¹
ãŠåå¿ãããçµæã¯ç¬¬ïŒè¡šã«ç€ºããã
ãè¡šã
å®æœäŸ ïŒ
å¥åžžäººãã10mlã®ãããªã³å éèè¡ãå
¥æã
ããããããããã€ã³ãŒã«ããã¯æ¶²ã§åŠçãããª
ã³ãçç»åãå«ãã¢ããã¯ãªã¢ãŒã»ã«ãåé¢ã
ãããã®ã¢ããã¯ãªã¢ãŒã»ã«ïŒÃ106åã«ãB95
âïŒæ ªã®å¹é€äžæž äžã«å«ãŸããâãŠã€ã«ã¹
ïŒãã©ã³ã¹ããªãŒã¡ãŒã·ãšã³ ããŒã¹50TD50ïŒ
105ïŒmlïŒãm.o.iïŒææã®å€éæ§ïŒã0.1ãšããŠæ
æãããã次ãã§ãïŒÃ105ïŒmlã«ãªãæ§ã«ã20
ïŒ FCS RPMIå¹å°ã§åžéãè¡ãããã®100ÎŒã¥
ã€ã96ç©Žå¹³åºãã¬ãŒãã«å ¥ããçŽïŒé±éCO2ã€ã³
ããŠããŒã¿ã§å¹é€ãè¡ã€ããçè²ãã圢質転æ现
èã®å¹é€äžæž 液ããç·è¿èã³ãŒãã€ã³ã°ãããã¬
ãŒãã§ELISAæ³ã«ããã¢ãã»ã€ããçµæã
Hommaã®è¡æž åïŒïŒïŒïŒïŒã®ããããã®èæ ªã«
åå¿ããäžæž 液ãç£çãã圢質転æ现èãéžå¥ã
ãããè»å¯å€©å¹é€ã§ãããã®çŽ°èãã¯ããŒãã³ã°
ãã第ïŒè¡šã®ãããªæç·è¿èããã¢ãã¯ããŒãã«
æäœãç£çãã圢質现èæ ªãæš¹ç«ããã
ããããããããã€ã³ãŒã«ããã¯æ¶²ã§åŠçãããª
ã³ãçç»åãå«ãã¢ããã¯ãªã¢ãŒã»ã«ãåé¢ã
ãããã®ã¢ããã¯ãªã¢ãŒã»ã«ïŒÃ106åã«ãB95
âïŒæ ªã®å¹é€äžæž äžã«å«ãŸããâãŠã€ã«ã¹
ïŒãã©ã³ã¹ããªãŒã¡ãŒã·ãšã³ ããŒã¹50TD50ïŒ
105ïŒmlïŒãm.o.iïŒææã®å€éæ§ïŒã0.1ãšããŠæ
æãããã次ãã§ãïŒÃ105ïŒmlã«ãªãæ§ã«ã20
ïŒ FCS RPMIå¹å°ã§åžéãè¡ãããã®100ÎŒã¥
ã€ã96ç©Žå¹³åºãã¬ãŒãã«å ¥ããçŽïŒé±éCO2ã€ã³
ããŠããŒã¿ã§å¹é€ãè¡ã€ããçè²ãã圢質転æ现
èã®å¹é€äžæž 液ããç·è¿èã³ãŒãã€ã³ã°ãããã¬
ãŒãã§ELISAæ³ã«ããã¢ãã»ã€ããçµæã
Hommaã®è¡æž åïŒïŒïŒïŒïŒã®ããããã®èæ ªã«
åå¿ããäžæž 液ãç£çãã圢質転æ现èãéžå¥ã
ãããè»å¯å€©å¹é€ã§ãããã®çŽ°èãã¯ããŒãã³ã°
ãã第ïŒè¡šã®ãããªæç·è¿èããã¢ãã¯ããŒãã«
æäœãç£çãã圢質现èæ ªãæš¹ç«ããã
ãè¡šã
ããã€ã³ããã·ãšã³ãã¹ãã§æ±ºå®ããã
å®æœäŸ 10 å®æœäŸïŒãšã¯ç°ãå¥åžžäººãããããªã³å éèè¡
ãå ¥æãããå®æœäŸïŒãšåãæ¹æ³ã§ãæç·è¿èã
ãâã¢ãã¯ããŒãã«æäœãç£çããâãŠã€ã«
ã¹åœ¢è³ªè»¢æãã现èãã¯ããŒãã³ã°ããããã®çµ
æã第10è¡šã«ç€ºããã
å®æœäŸ 10 å®æœäŸïŒãšã¯ç°ãå¥åžžäººãããããªã³å éèè¡
ãå ¥æãããå®æœäŸïŒãšåãæ¹æ³ã§ãæç·è¿èã
ãâã¢ãã¯ããŒãã«æäœãç£çããâãŠã€ã«
ã¹åœ¢è³ªè»¢æãã现èãã¯ããŒãã³ã°ããããã®çµ
æã第10è¡šã«ç€ºããã
ãè¡šã
ã€ã³ããã·ãšã³ãã¹ãã§æ±ºå®ããã
Hommaæšæºè¡æž åïŒåã10åã®ããããã®è
æ ªã«åå¿ããã¢ãã¯ããŒãã«æäœãç£çãã圢質
転æãã现èæ ªãæš¹ç«ã§ããããŸããSE11æ ªã¯ã
ïŒåãïŒåã13åã®ãããã«ãåå¿ãããšããã
ããŒããªæ§è³ªã瀺ããã å®æœäŸ 11 ç°ãå¥åžžäººãããããªã³å è¡éèãå ¥æããã
å®æœäŸïŒãšåãæ¹æ³ã§ãæç·è¿èããã¢ãã¯ããŒ
ãã«æäœãç£çããâãŠã€ã«ã¹åœ¢è³ªè»¢æ现è
ãã¯ããŒãã³ã°ããããã®ã¯ããŒãã³ã°çŽ°èæ ªã®
æ§ç¶ã第11è¡šã«ç€ºããã
Hommaæšæºè¡æž åïŒåã10åã®ããããã®è
æ ªã«åå¿ããã¢ãã¯ããŒãã«æäœãç£çãã圢質
転æãã现èæ ªãæš¹ç«ã§ããããŸããSE11æ ªã¯ã
ïŒåãïŒåã13åã®ãããã«ãåå¿ãããšããã
ããŒããªæ§è³ªã瀺ããã å®æœäŸ 11 ç°ãå¥åžžäººãããããªã³å è¡éèãå ¥æããã
å®æœäŸïŒãšåãæ¹æ³ã§ãæç·è¿èããã¢ãã¯ããŒ
ãã«æäœãç£çããâãŠã€ã«ã¹åœ¢è³ªè»¢æ现è
ãã¯ããŒãã³ã°ããããã®ã¯ããŒãã³ã°çŽ°èæ ªã®
æ§ç¶ã第11è¡šã«ç€ºããã
ãè¡šã
ã€ã³ããã·ãšã³ãã¹ãã§æ±ºå®ããã
å®æœäŸ 12 ææ¡è ºçŽ°èãããææ¡è ºãã調補ããå®æœäŸïŒ
ãšåãæ¹æ³ã§ãæç·è¿èããã¢ãã¯ããŒãã«æäœ
ãç£çããâãŠã€ã«ã¹åœ¢è³ªè»¢æ现èïŒâ3D8
ãã¯ããŒãã³ã°ãããïŒâ3D8ã¯IgMã§ã
Hommaæšæºè¡æž åtype5ãšã®ã¿åå¿ããã 次ã«ãè¡æž åãtype5ã«å±ããç·è¿èïŒæ ªãšã®
çµåç¹ç°æ§ã調ã¹ããšããã第12è¡šã«ç€ºãããã
ã«ãïŒæ ªäžïŒæ ªã«åå¿ããã
å®æœäŸ 12 ææ¡è ºçŽ°èãããææ¡è ºãã調補ããå®æœäŸïŒ
ãšåãæ¹æ³ã§ãæç·è¿èããã¢ãã¯ããŒãã«æäœ
ãç£çããâãŠã€ã«ã¹åœ¢è³ªè»¢æ现èïŒâ3D8
ãã¯ããŒãã³ã°ãããïŒâ3D8ã¯IgMã§ã
Hommaæšæºè¡æž åtype5ãšã®ã¿åå¿ããã 次ã«ãè¡æž åãtype5ã«å±ããç·è¿èïŒæ ªãšã®
çµåç¹ç°æ§ã調ã¹ããšããã第12è¡šã«ç€ºãããã
ã«ãïŒæ ªäžïŒæ ªã«åå¿ããã
ãè¡šã
å®æœäŸ 13
ç·è¿èâ64æ ªïŒHomma type6ïŒãICRããŠ
ã¹ïŒïŒé±ä»€ãéãäžçŸ€ïŒå¹ïŒã®è ¹è ã«ïŒÃ107å
ïŒ2LD50ïŒææåŸïŒæéããŠãå®æœäŸ10ã§åŸãã
ã圢質転æ现èSE10ããç²ç²Ÿè£œïŒç¡«é žã¢ã³ã¢ã
ãŠã æ²æŸ±ïŒããã¢ãã¯ããŒãã«æäœïŒMCAâ
SE10ïŒãæäžããææé²åŸ¡ãæç«ãããã©ãã
調ã¹ããSE10ã®ç£çããæäœéã¯ãã·ã³ã°ã«ã©
ãã€ã¢ã«ã€ããŠããã€ããŠãŒãžãšã³æ³ã«ããç®åº
ãããã³ã³ãããŒã«ã¢ãã¯ããŒãã«æäœãšããŠã
å®æœäŸ12ã®type5ã«åå¿ããïŒâ3D8ïŒMCAâïŒ
â3D8ïŒãçšãããçµæã第13è¡šã«ç€ºããã
ã¹ïŒïŒé±ä»€ãéãäžçŸ€ïŒå¹ïŒã®è ¹è ã«ïŒÃ107å
ïŒ2LD50ïŒææåŸïŒæéããŠãå®æœäŸ10ã§åŸãã
ã圢質転æ现èSE10ããç²ç²Ÿè£œïŒç¡«é žã¢ã³ã¢ã
ãŠã æ²æŸ±ïŒããã¢ãã¯ããŒãã«æäœïŒMCAâ
SE10ïŒãæäžããææé²åŸ¡ãæç«ãããã©ãã
調ã¹ããSE10ã®ç£çããæäœéã¯ãã·ã³ã°ã«ã©
ãã€ã¢ã«ã€ããŠããã€ããŠãŒãžãšã³æ³ã«ããç®åº
ãããã³ã³ãããŒã«ã¢ãã¯ããŒãã«æäœãšããŠã
å®æœäŸ12ã®type5ã«åå¿ããïŒâ3D8ïŒMCAâïŒ
â3D8ïŒãçšãããçµæã第13è¡šã«ç€ºããã
ãè¡šã
ïŒ ããŠã¹ã®çåç
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ç·è¿èã®è¡æž åãïŒåãïŒåãïŒåãïŒåå
ã³10åã®ããããã§ãã€ãŠã該ç·è¿èã®ãªãå€ç³
ã®ïŒ¯âå€ç³åŽéãèªèããæ§è³ªãæããããã®æ
ç·è¿èæäœç£ç现èãšããŠã¹ã®ããšããŒã现èãš
ã®ããŠã¹âãããã€ããªããŒãç±æ¥ã®æç·è¿èã
ãã¢ãã¯ããŒãã«IgGæäœã ïŒ ããã®æç·è¿èæäœç£ç现èãšããŠã¹ã®ããš
ããŒã现èãšã®ããŠã¹âãããã€ããªããŒããäœ
æãã該ãã€ããªããŒãåã³ïŒåã¯ããã«ç±æ¥ã
ã现èæ ªãå¹é€ããå¹é€ç©ããç·è¿èã®è¡æž åã
ïŒåãïŒåãïŒåãïŒååã³10åã®ããããã§ã
ã€ãŠã該ç·è¿èã®ãªãå€ç³ã®ïŒ¯âå€ç³åŽéã«çµå
ããæ§è³ªãæããããã¢ãã¯ããŒãã«IgGæäœã
æ¡åããããšãããªããæç·è¿èããã¢ãã¯ããŒ
ãã«IgGæäœã®è£œé æ³ã ïŒ ç·è¿èã®è¡æž åãïŒåãïŒåãïŒåãïŒåå
ã³10åããããã§ãã€ãŠã該ç·è¿èã®ãªãå€ç³ã®
âå€ç³åŽéãèªèããæ§è³ªãæããããã®æç·
è¿èæäœç£ç现èãšããŠã¹ã®ããšããŒã现èãšã®
ããŠã¹âãããã€ããªããŒãç±æ¥ã®æç·è¿èãã
ã¢ãã¯ããŒãã«IgGæäœãæå¹æåãšããç·è¿è
ææçæ²»çå€ã
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27465984A JPS61155398A (ja) | 1984-12-28 | 1984-12-28 | æç·è¿èããã¢ãã¯ãâãã«æäœåã³ãã®è£œé æ³äžŠã³ã«ãããæå¹æåãšããæ²»çå€ |
AT86900258T ATE86634T1 (de) | 1984-12-26 | 1985-12-20 | Humaner monoklonaler antikoerper gegen pseudomonas aeruginosagegen pseudomonas aeruginosa produzierende hybridomen. |
EP86900258A EP0233289B1 (en) | 1984-12-26 | 1985-12-20 | Hybridomas producing anti-pseudomonas aeruginosa human monoclonal antibody |
PCT/JP1985/000698 WO1986003754A1 (en) | 1984-12-26 | 1985-12-20 | Anti-pseudomonas aeruginosa human monoclonal antibody |
DE8686900258T DE3587178T2 (de) | 1984-12-26 | 1985-12-20 | Humaner monoklonaler antikoerper gegen pseudomonas aeruginosagegen pseudomonas aeruginosa produzierende hybridomen. |
AU53093/86A AU597877B2 (en) | 1984-12-26 | 1985-12-20 | Anti-pseudomonas aeruginosa human monoclonal antibody |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27465984A JPS61155398A (ja) | 1984-12-28 | 1984-12-28 | æç·è¿èããã¢ãã¯ãâãã«æäœåã³ãã®è£œé æ³äžŠã³ã«ãããæå¹æåãšããæ²»çå€ |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS61155398A JPS61155398A (ja) | 1986-07-15 |
JPH0361428B2 true JPH0361428B2 (ja) | 1991-09-19 |
Family
ID=17544768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP27465984A Granted JPS61155398A (ja) | 1984-12-26 | 1984-12-28 | æç·è¿èããã¢ãã¯ãâãã«æäœåã³ãã®è£œé æ³äžŠã³ã«ãããæå¹æåãšããæ²»çå€ |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61155398A (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU591017B2 (en) * | 1986-12-15 | 1989-11-23 | Mitsui Toatsu Chemicals Inc. | Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58128323A (ja) * | 1982-01-22 | 1983-07-30 | ãµã³ãã»ã¢ã¯ããšã³ã²ãŒã«ã·ã€ãã | ããã¢ãã¯ãâã³æäœã®è£œé æ³ |
JPS58216125A (ja) * | 1982-06-09 | 1983-12-15 | Asahi Chem Ind Co Ltd | ããæäœã®ç£çæ¹æ³ |
JPS60248626A (ja) * | 1984-05-25 | 1985-12-09 | Mitsui Toatsu Chem Inc | ç·è¿èææçã®äºé²æ²»çå€ |
JPS6169796A (ja) * | 1984-05-25 | 1986-04-10 | ãžãšããã€ã¯ãã·ã¹ãã ãºãã³âãã¬ã€ã·ãšã³ | ããã¢ãã¯ãâãã«æäœ |
-
1984
- 1984-12-28 JP JP27465984A patent/JPS61155398A/ja active Granted
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58128323A (ja) * | 1982-01-22 | 1983-07-30 | ãµã³ãã»ã¢ã¯ããšã³ã²ãŒã«ã·ã€ãã | ããã¢ãã¯ãâã³æäœã®è£œé æ³ |
JPS58216125A (ja) * | 1982-06-09 | 1983-12-15 | Asahi Chem Ind Co Ltd | ããæäœã®ç£çæ¹æ³ |
JPS60248626A (ja) * | 1984-05-25 | 1985-12-09 | Mitsui Toatsu Chem Inc | ç·è¿èææçã®äºé²æ²»çå€ |
JPS6169796A (ja) * | 1984-05-25 | 1986-04-10 | ãžãšããã€ã¯ãã·ã¹ãã ãºãã³âãã¬ã€ã·ãšã³ | ããã¢ãã¯ãâãã«æäœ |
Also Published As
Publication number | Publication date |
---|---|
JPS61155398A (ja) | 1986-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0394946A2 (en) | Human monoclonal antibody, and its production and use | |
OA10213A (en) | Oral treatment of helicobacter infection | |
FR2593826A1 (fr) | Anticorps monoclonaux a reactivite et a protectivite croisees vis-a-vis des serotypes de p. aeruginosa | |
US4834976A (en) | Monoclonal antibodies to pseudomonas aeruginosa flagella | |
JP2645343B2 (ja) | 亀差é²åŸ¡æ§ããåã¯ããŒã³æ§æäœãŸãã¯ãã®çµåãã©ã°ã¡ã³ããå«ãå»è¬çµæç© | |
AU597877B2 (en) | Anti-pseudomonas aeruginosa human monoclonal antibody | |
EP0057107A2 (en) | Method of manufacturing monoclonal antibodies and cells capable of manufacturing such antibodies | |
AU615162B2 (en) | Monoclonal antibodies to pseudomonas aeruginosa flagella | |
KR900000546B1 (ko) | ë ¹ëê· ì E 87 Ag íì ë° ê·žê²ì ëí ëªšë žíŽë¡ë í첎 ë° íìŽëžëŠ¬ëë§ | |
KR910004868B1 (ko) | ìžì²Ž ëšìŒ íŽë¡ í첎 ë° ê·žê²ì íì±ì±ë¶ìŒë¡ íšì íë ê°ìŒìŠì ìë°© ë° ì¹ë£ì© ìœíì ì ì | |
JPH0361428B2 (ja) | ||
EP0259807B1 (en) | Complement-dependent cytolytic anti-trichomonas vaginalis monoclonal antibody and use thereof in therapy and in diagnosis | |
JPS60248626A (ja) | ç·è¿èææçã®äºé²æ²»çå€ | |
HU205630B (en) | Process for producing monoclonal antibodys inhibiting exotoxine and toxic effect of pseudomonas aeruginosa and specific for them, celle lines producing them and pharmaceutical compositions | |
JPH0355106B2 (ja) | ||
EP0326148A1 (en) | Human monoclonal antibody specific for Pseudomonas aeruginosa and hybrid cell lines | |
JPS61152280A (ja) | æç·è¿èããæäœãç£çãã圢質転æ现èåã³ãã®è£œé æ³äžŠã³ã«ãã®äœ¿çšæ¹æ³ | |
JPS59186923A (ja) | ããåç«è ºçæ²»ççšè¬å€ | |
JPS59186926A (ja) | ã¢ã¹ãã«ã®ã«ã¹èææçæ²»ççšè¬å€ | |
JPS59186925A (ja) | ã«ã³ãžãèææçæ²»ççšè¬å€ | |
JPS63107999A (ja) | æ²»ççšããæã·ãŠâãã¢ãã¹ã»ã¢ãšã«ã®ããµæäœ | |
JPH0662886A (ja) | ã¢ãã¯ãâãã«æäœåã³ãã®çšé | |
JPH05203653A (ja) | ã¢ã¹ãã«ã®ã«ã¹èã®åé¡ããã³åå®çšè©Šè¬ | |
KR20030083617A (ko) | ìë§ìŒê· ìŠ ë°±ì ì¡°ì±ë¬Œ |